Ligand acquires life cycle management technology company CyDex
This article was originally published in Scrip
Executive Summary
Ligand Pharmaceuticals is forking out $31.2 million up front to acquire CyDex Pharmaceuticals to accelerate its financial growth, expand the portfolio, and provide a drug reformulation platform.